Pear Therapeutics announced the publication of real-world data analyzing healthcare resource utilization for reSET-O, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD), in the peer-reviewed journal Expert Review of Pharmacoeconomics & Outcomes Research.
The study provides real-world evidence of the economic value of reSET-O. The new real-world data showed a robust decrease in costly healthcare utilization categories in patients with OUD. These results indicate a strong potential for the cost effectiveness of reSET-O in real-world care settings.
In the study, retrospective real-world claims analysis evaluated healthcare resource utilization up to six months after reSET-O initiation. reSET-O use was associated with fewer inpatient, intensive care unit, emergency department, and other clinical encounters, lowering net healthcare costs over six months. Decreased healthcare utilization reduced overall healthcare spend by $2,150 per patient.
Study results for real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic:
- Among 351 patients (mean age 37; 59.5% female; 82.6% Medicaid), there were 228 pre-index (i.e., six months pre-reSET-O initiation) and 153 post-index (i.e., six months post-reSET-O initiation) unique hospital-related visits in this population (pre-index medication possession ratio = 0.76).
- This reduction represents a total of 75 unique facility encounters avoided in this cohort (i.e., ~one event was avoided per five treated patients), including 45 inpatient hospital stays (four of which included ICU stays), and 27 emergency department visits.
- Overall, there were approximately 1,181 fewer claims post-index across the 351 patients, with a corresponding $2,150 projected reduction in healthcare spending for each patient treated with reSET-O (using 2020 CMS fee schedule).
On the record
“These newly shared data reinforce how reSET-O can improve total quality of care while reducing the main healthcare cost drivers in OUD,” said Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics. “Real-world patient outcomes support the cost-impact of reSET-O. Payers who are not providing access to the product are sacrificing better outcomes and healthcare savings.”
The full paper is available online from here.
Digital therapeutics are one of the growing areas and we briefly cover it along other technologies that are changing healthcare in our new report “Introduction to Digital Health.” It is now available for purchase from DHbriefs.com.